What is Vertex Pharmaceuticals's market cap?

Vertex Pharmaceuticals (VRTX) has a market capitalization of $126.50B and trades on NASDAQ.

What is Vertex Pharmaceuticals's revenue and profitability?

Vertex Pharmaceuticals generated $12.2B in trailing twelve-month revenue with net income of $4.3B, representing a net margin of 35.5%. Gross margin stands at 86.2%, with free cash flow of $3.7B. These figures are based on the Q1 2026 filing.

Who are Vertex Pharmaceuticals's competitors?

Vertex Pharmaceuticals's key competitors include AbbVie, Fulcrum Therapeutics, Inc. Common Stock, Sionna Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Vertex Pharmaceuticals partner with?

Vertex Pharmaceuticals's notable partners include CRISPR Therapeutics.

What subsidiaries does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals's subsidiaries include Alpine Immune Sciences.

Where is Vertex Pharmaceuticals headquartered?

Vertex Pharmaceuticals is headquartered in United States of America and employs approximately 5,400 people. It has been publicly traded since 1991.

Vertex Pharmaceuticals

VRTX

Vertex Pharmaceuticals is a global biotechnology company dedicated to developing transformative medicines for serious diseases with a focus on specialty markets.

Market cap

$126.5B+7.2%

Revenue$12.2B+10.1%

Net income$4.3B+641%

Free cash flow$3.7B+208%

EPS (diluted)$16.85+625%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$3.0BMiss by $7.3M EPS$4.47Beat by $0.23

Read the full report

Next report

Aug 3, 2026 (In 3 weeks)

Revenue estimate$3.2B

EPS estimate$4.72

Financials

Q1 2026

Income statement

See full

Revenue$3.0B+7.8%

Gross profit$2.6B+7.8%

Operating income$1.1B+80.6%

Net income$1.0B+59.6%

EPS (diluted)$4.02+61.4%

Balance sheet

See full

Cash & equivalents$5.5B+17.5%

Total debt$2.0B+20.5%

Total equity$19.4B+17.4%

Total assets$26.5B+15.8%

Cash flow

See full

Operating cash flow$1.4B+74.4%

CapEx$133.4M+228%

Free cash flow$1.3B+66.4%

Valuation & ratios

Valuation

See full

Market cap$126.5B+7.2%

Enterprise value$122.99B+7.3%

P/E29.2×—

P/S10.4×0.0×

Profitability

See full

Gross margin86.2%+0.2pp

Operating margin38.3%—

Net margin35.5%—

FCF margin30.4%+20.2pp

Returns & leverage

See full

Return on equity24.2%—

Debt / equity0.1×0.0×

Current ratio3×+0.4×

Segments

By product

See full

TRIKAFTA/KAFTRIO$2.4B-7.1%

ALYFTREK$424.4M+687%

Other CF product revenues$135.9M-12.5%

CASGEVY$42.9M—

JOURNAVX$29.0M—

By geography

See full

Europe$950.0M+14.9%

Other$261.0M-6.8%

By segment

See full

Pharmaceuticals$3.0B+7.8%

Competitors

By market cap

AbbVie$446.54B+33.6%

Vertex Pharmaceuticals$126.50B+7.2%

BridgeBio Pharma$15.3B+83.7%

Sionna Therapeutics, Inc.$2.0B+113%

Zevra Therapeutics, Inc.$871.9M+63.7%

CytomX Therapeutics$833.8M+112%

Gyre Therapeutics, Inc.$764.8M+3.8%

Fulcrum Therapeutics, Inc.$248.5M-33.5%

By revenue growth

BridgeBio Pharma+355%

Zevra Therapeutics, Inc.+201%

Gyre Therapeutics, Inc.+16.3%

Vertex Pharmaceuticals+10.1%

AbbVie+9.5%

CytomX Therapeutics-75.9%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

Vertex Pharmaceuticals35.51%+42.7pp

Gyre Therapeutics, Inc.6.29%-13.8pp

AbbVie5.79%-1.5pp

BridgeBio Pharma-125.85%+405pp

CytomX Therapeutics-166.4%-195pp

Profile

Vertex Pharmaceuticals is a global biotechnology company dedicated to developing transformative medicines for serious diseases with a focus on specialty markets. The company leverages a serial innovation strategy to discover and commercialize therapies that address the underlying causes of diseases such as cystic fibrosis, sickle cell disease, and acute pain. Their approach combines deep human biology insights with advanced therapeutic modalities to deliver first-in-class and best-in-class treatments.

Competitive position

Vertex is the dominant leader in the cystic fibrosis market and a pioneer in CRISPR-based gene editing and non-opioid pain treatments.

GeographiesUnited States, Europe, Australia, Canada

Customer segmentsPatients with rare diseases, Specialized healthcare systems, Government health programs

Business modelR&D-driven drug development, Specialty pharmaceutical commercialization

SuppliersSpecialized raw material suppliers, Contract manufacturing organizations, Academic research institutions, Genetic sequencing providers

CustomersSpecialty drug distributors, Public and private insurers, Specialized medical centers

CountryUnited States of America

Listed1991

Employees5.4K

CEOReshma Kewalramani

SectorHealthcare

IndustryBiotechnology

Websitevrtx.com

FilingsSEC EDGAR

Ask your AI about Vertex Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vertex Pharmaceuticals's market cap?: Vertex Pharmaceuticals (VRTX) has a market capitalization of $126.50B and trades on NASDAQ.
What is Vertex Pharmaceuticals's revenue and profitability?: Vertex Pharmaceuticals generated $12.2B in trailing twelve-month revenue with net income of $4.3B, representing a net margin of 35.5%. Gross margin stands at 86.2%, with free cash flow of $3.7B. These figures are based on the Q1 2026 filing.
Who are Vertex Pharmaceuticals's competitors?: Vertex Pharmaceuticals's key competitors include AbbVie, Fulcrum Therapeutics, Inc. Common Stock, Sionna Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Vertex Pharmaceuticals partner with?: Vertex Pharmaceuticals's notable partners include CRISPR Therapeutics.
What subsidiaries does Vertex Pharmaceuticals have?: Vertex Pharmaceuticals's subsidiaries include Alpine Immune Sciences.
Where is Vertex Pharmaceuticals headquartered?: Vertex Pharmaceuticals is headquartered in United States of America and employs approximately 5,400 people. It has been publicly traded since 1991.